Apollomics Reports Full Year 2025 Financial Results and Clinical Updates

Apollomics Inc., a clinical-stage biopharmaceutical company, reported its financial results for the full year ended December 31, 2025, emphasizing the development of its lead drug vebreltinib for patients with c-MET alterations in various tumors. The company plans to submit an Investigational New Drug Application for accelerated approval of vebreltinib for NSCLC patients in the first half of 2027, following guidance from the FDA.